Google
VRAX Stock Price & Analysis — Virax Biolabs Group Limited Ordinary Shares (Healthcare >> Biotechnology)
VRAX FAQ
What is VRAX's ROE?
Virax Biolabs Group Limited Ordinary Shares reports a Return on Equity (ROE) of -177.16%.
What is VRAX's dividend yield?
Virax Biolabs Group Limited Ordinary Shares offers a dividend yield of 0.00%.
What is VRAX's Quality Score?
Our AI rates VRAX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VRAX?
Our AI Timing Score for VRAX is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VRAX belong to?
Virax Biolabs Group Limited Ordinary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
VRAX AI Analysis Summary
Our AI summary for VRAX: Virax Biolabs Group Limited Ordinary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -177.16%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.77
Price
-0.14
(-4.81%)
Day Change
|
|
|---|
VRAX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.77 |
| PBV / Sector |
0.30 / 5.21
GREAT
|
| Earning Per Share | -16.84 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
3.34 M
GREAT
|
| Average 1W Daily Value |
0.22 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-07 08:12:31 |
| Symbol | VRAX |
| Name | VIRAX BIOLABS GROUP LIMITED ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2.21 / 9,672.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH
Phone: 44 20 7788 7414
Website: https://viraxbiolabs.com
Sector: Healthcare >> Biotechnology
Description: Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap